Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238958 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL10238942 | 1.00 | P2RY2 (0.31) | P2RY2P2RY4 | |
| SCHEMBL10238937 | 0.96 | P2RY2 (0.30) | P2RY2P2RY4 | |
| SCHEMBL10238938 | 0.96 | P2RY2 (0.30) | P2RY2P2RY4 | |
| SCHEMBL10238952 | 0.96 | P2RY2 (0.30) | P2RY2P2RY4 | |
| SCHEMBL1591988 | 0.88 | P2RY2 (0.32) | P2RY2P2RY4 | |
| SCHEMBL18561541 | 0.85 | P2RY2 (0.41) | P2RY2P2RY4 | |
| SCHEMBL17357584 | 0.85 | P2RY2 (0.41) | P2RY2P2RY4 | |
| SCHEMBL14946250 | 0.85 | P2RY2 (0.41) | P2RY2P2RY4 | |
| SCHEMBL12170352 | 0.85 | P2RY2 (0.41) | P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774106-B2 | Uracyl spirooxetane nucleosides | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-15 | — | — | US | disclosed |
| US-20200109161-A1 | URACYL SPIROOXETANE NUCLEOSIDES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-04-09 | — | — | US | disclosed |
| US-10040814-B2 | Uracyl spirooxetane nucleosides | JANSSEN SCIENCES IRELAND UC (IE) | 2018-08-07 | — | — | US | disclosed |
| US-20180099990-A1 | URACYL SPIROOXETANE NUCLEOSIDES | Janssen Sciences Ireland Unlimited Company (IE) | 2018-04-12 | — | — | US | disclosed |
| US-9845336-B2 | Uracyl spirooxetane nucleosides | JANSSEN SCIENCES IRELAND UC (IE) | 2017-12-19 | — | — | US | disclosed |
| US-20170145045-A1 | URACYL SPIROOXETANE NUCLEOSIDES | Janssen Sciences Ireland Unlimited Company (IE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145045-A1 | URACYL SPIROOXETANE NUCLEOSIDES | Janssen Sciences Ireland Unlimited Company (IE) | 2017-05-25 | — | — | US | disclosed |
| US-9422323-B2 | Uracyl spirooxetane nucleosides | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-20150141365-A1 | URACYL SPIROOXETANE NUCLEOSIDES | JANSSEN R&D IRELAND (IE) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141365-A1 | URACYL SPIROOXETANE NUCLEOSIDES | SLC28A1, NUDT1, UMPS | P2RY2 1529/4885P2RY4 1114/4885 |
| US-20200109161-A1 | URACYL SPIROOXETANE NUCLEOSIDES | SLC28A1, NUDT1, UMPS | P2RY2 1681/4885P2RY4 1284/4885 |
| US-10040814-B2 | Uracyl spirooxetane nucleosides | SLC28A1, NUDT1, UMPS | P2RY2 1529/4885P2RY4 1114/4885 |
| US-20170145045-A1 | URACYL SPIROOXETANE NUCLEOSIDES | SLC28A1, NUDT1, UMPS | P2RY2 1529/4885P2RY4 1114/4885 |
| US-20180099990-A1 | URACYL SPIROOXETANE NUCLEOSIDES | SLC28A1, NUDT1, UMPS | P2RY2 1681/4885P2RY4 1284/4885 |
| US-10774106-B2 | Uracyl spirooxetane nucleosides | SLC28A1, NUDT1, UMPS | P2RY2 1529/4885P2RY4 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.